CAR T-Cell Therapy Advances Long-Term Disease Control in Relapsed or Refractory Multiple Myeloma
Clinical Summary:
- Marc Braunstein, MD, PhD, examines the evolving role of CAR T-cell therapy in relapsed or refractory multiple myeloma, including long-term remission outcomes, emerging BCMA-directed therapies, and novel allogeneic and in vivo CAR T-cell approaches.
- Long-term follow-up from CAR T-cell trials has demonstrated sustained treatment-free remissions in a subset of patients, while emerging therapies such as anitocabtagene autoleucel show promising activity and favorable safety profiles.
- These developments support the expanding role of CAR T-cell therapy in multiple myeloma and highlight the potential for next-generation cellular therapies to improve treatment accessibility, reduce toxicity, and achieve durable disease control.
Marc Braunstein, MD, PhD, NYU Perlmutter Cancer Center and NYU Grossman Long Island School of Medicine, New York, New York, discusses advances in CAR T-cell therapy for patients with relapsed or refractory multiple myeloma, including long-term remission outcomes and emerging cellular immunotherapy strategies.
Dr Braunstein reviews long-term follow-up data supporting the potential for sustained treatment-free remission following CAR T-cell therapy, as well as emerging results with anitocabtagene autoleucel, a novel BCMA-directed CAR T-cell therapy. He also discusses the development of allogeneic and in vivo CAR T-cell approaches, highlighting their potential to simplify treatment delivery, improve accessibility, and expand cellular therapy options for patients with relapsed or refractory multiple myeloma.
